What's Happening?
Novartis announced that its antisense therapy, pelacarsen, failed to meet its primary endpoint in the Phase 3 Lp(a)HORIZON study, showing no significant benefit in lowering the risk of cardiovascular events. This outcome occurred despite pelacarsen's
previous success in mid-stage studies, where it achieved up to an 80% reduction in lipoprotein(a) (Lp(a)) levels. The primary endpoint of the study was to reduce the risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization. This failure, along with other recent setbacks for Novartis, led to a 12% plunge in its stock price. Analysts from William Blair and BMO Capital Markets view this as a significant setback for therapies specifically targeting Lp(a) to reduce cardiovascular risk, raising questions about the validity of Lp(a) as a therapeutic target.
Why It's Important?
The failure of Novartis' pelacarsen in a late-stage trial is a major blow to the pharmaceutical industry's efforts to develop therapies for cardiovascular disease by targeting Lp(a). Lp(a) has been a significant focus for many biotech companies, including Eli Lilly and Amgen, which are also developing Lp(a)-lowering therapies. This outcome raises the 'burden of proof' for these other investigational assets, such as Lilly's lepodisiran and Amgen's olpasiran, which are currently in late-stage trials. The setback could lead to a re-evaluation of the scientific hypothesis that lowering Lp(a) levels directly translates to a reduction in cardiovascular events. This could impact investment in Lp(a)-targeted therapies and potentially shift research focus to other mechanisms for cardiovascular risk reduction, affecting millions of patients at risk of heart disease.
What's Next?
Novartis has not yet provided specific data from the Lp(a)HORIZON study but plans to do so at a future medical congress. The industry will closely watch the outcomes of other ongoing Phase 3 trials for Lp(a)-lowering therapies, particularly Lilly's ACCLAIM-Lp(a) trial for lepodisiran (expected in 2029) and Amgen's OCEAN(a) study for olpasiran (slated for 2028). While the failure of pelacarsen casts a shadow, some analysts still hold hope for Amgen's olpasiran, citing its 'deeper' Lp(a) reduction and the enrollment of a higher-risk population in its trial. Merck also has an Lp(a) inhibitor, HRS-5346, in development through a partnership with Jiangsu Hengrui. The coming years will be critical in determining the future of Lp(a) as a viable therapeutic target for cardiovascular disease.
Beyond the Headlines
The pelacarsen trial's failure highlights a recurring challenge in drug development: the translation of biomarker reduction into meaningful clinical outcomes. While Lp(a) reduction was achieved, it did not translate into a significant decrease in cardiovascular events, suggesting that the relationship between Lp(a) levels and cardiovascular risk might be more complex than initially understood, or that other confounding factors are at play. This outcome could prompt a deeper scientific inquiry into the precise mechanisms by which Lp(a) contributes to cardiovascular disease and whether simply lowering its levels is sufficient. It also underscores the need for robust clinical trial designs that can definitively prove clinical benefit, rather than relying solely on biomarker changes. The broader implications extend to how the pharmaceutical industry approaches drug discovery for complex multifactorial diseases, emphasizing the importance of understanding the full biological context.
